FDA Signals Potential Expansion of Testosterone Therapy to Treat Low Libido in Idiopathic Hypogonadism

The FDA is taking an initial step toward expanding treatment options for men’s health by signaling openness to a new indication for testosterone replacement therapy (TRT).¹ The agency is encouraging sponsors of approved TRT products to engage with regulators if they are interested in pursuing approval for treating low libido in men with idiopathic hypogonadism, defined as low testosterone levels without a known structural or genetic cause.

Currently, FDA-approved TRT products are limited to men with hypogonadism linked to specific underlying conditions, such as genetic disorders or damage to the testes or pituitary gland. However, following a review of emerging clinical evidence and input from a December 2025 expert panel, the FDA identified data suggesting TRT may be both safe and effective for certain men experiencing low libido associated with idiopathic hypogonadism.

“New and emerging data suggest there may be an opportunity to help men suffering from symptoms that significantly affect quality of life,” said FDA Commissioner Marty Makary, MD, MPH, in a statement. “We are eager to work with sponsors to further evaluate this potential new use while upholding our rigorous standards for safety and effectiveness.”

The FDA’s preliminary assessment focused on published, well-controlled clinical trials evaluating outcomes related to sexual health and testosterone levels. Based on these findings, the agency is inviting holders of approved new drug applications (NDAs) for TRT products to consider submitting supplemental NDAs to support the proposed indication. Sponsors interested in pursuing this pathway were encouraged to contact the agency by April 30 to discuss data requirements and regulatory expectations.

This move reflects growing recognition of sexual health as a critical component of overall well-being. “Sexual health is an important component of overall well-being and quality of life,” said Brian J. Christine, MD, assistant secretary for Health at HHS, in a statement. “This is an exciting opportunity to build on new science and potentially expand treatment options for men with hypogonadism. We encourage continued innovation and collaboration to bring forward high-quality evidence that can expand options for men with hypogonadism.”

Despite this openness, the FDA underscored that any new indication would require substantial evidence demonstrating that the therapy’s benefits outweigh its risks in the intended population. Testosterone therapies have historically been associated with safety concerns, including cardiovascular risks and potential misuse, prompting careful regulatory oversight.²

These concerns were highlighted in a separate FDA safety communication that introduced class-wide labeling changes for testosterone products. The updates aimed to better inform clinicians and patients about potential risks, including cardiovascular events and abuse potential, reinforcing the importance of appropriate patient selection and monitoring. The labeling changes also clarified approved uses, underscoring that TRT should not be prescribed for age-related declines in testosterone absent a diagnosable medical condition.

If future studies confirm the safety and efficacy of TRT for low libido in men with idiopathic hypogonadism, the approval of such an indication could represent a meaningful shift in the treatment landscape. It may also prompt further research into the broader role of testosterone in men’s health, including its impact on mood, energy, and overall quality of life.

Ultimately, collaboration between regulators, drug manufacturers, and the clinical community will be essential to translating emerging evidence into safe and effective treatment options. As the FDA continues to evaluate data and engage with stakeholders, the potential expansion of TRT indications may offer new hope for patients while reinforcing the importance of careful patient selection and monitoring.

References

1. FDA takes step forward on testosterone therapy for men. News release. FDA. April 16, 2026. Accessed April 16, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-issues-class-wide-labeling-changes-testosterone-products

2. FDA issues class-wide labeling changes for testosterone products. News release. FDA. February 28, 2025. Accessed April 16, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-issues-class-wide-labeling-changes-testosterone-products